Integrative Medicine
RSSArticles
-
Cardiovascular Benefits and Diabetes Risks of Statin Therapy
In the JUPITER primary prevention trial, the cardiovascular and mortality benefits of statin therapy exceeded the diabetes hazard, including patients at high risk of developing diabetes. -
Pharmacology Watch: Menopausal Hormone Therapy and the Risk for VTE, AD
Menopausal hormone therapy and risk of VTE and AD; patients' understanding of chemotherapy benefits; and FDA actions. -
ECG Review: The Coronaries Were Clean...
The ECG shown above was obtained from a 74-year-old woman who presented with abrupt onset of severe renal colic but no chest pain. -
Pharmacology Update: Perampanel Tablets (Fycompa)
The FDA has approved the first in class α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist for the treatment of seizures. Perampanel is an orally active noncompetitive AMPA antagonist. The drug is marketed by Eisai Inc. as Fycompa. -
Pharmacology Update: Brimonidine Tartrate Topical Gel (Mirvaso®)
A highly selective alpha-2 adrenergic receptor agonist has been approved by the FDA for the treatment of persistent facial erythema of rosacea in adults. -
Azithromycin — The Heart of the Matter Redux: Pre-existing Risks Tell the Tale
Svanström and colleagues in copenhagen examined the risk of cardiovascular deaths in association with azithromycin use in a nationwide historical cohort study of Danish adults aged 18-64 years. -
Internal Medicine Alert - Full September 29, 2013 Issue in PDF
-
Omega 3s and the Prostate: Good or Bad?
The role of omega-3 fatty acids in prostate cancer risk has been inconsistent and it has been difficult to draw practical and clinically useful conclusions from the research. -
Clinical Briefs By Louis Kuritzky
-
Effect of Dabigatran on Referrals to and Switching from Warfarin
Dabigatran has been demonstrated to decrease the rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) by one-third, while also decreasing the rate of intracranial bleeding by two-thirds compared with warfarin.